Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
- PMID: 10508491
- DOI: 10.1002/(sici)1097-0215(19991112)83:4<532::aid-ijc16>3.0.co;2-k
Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity
Abstract
Dendritic cells (DCs) are potent inducers of cytotoxic T lymphocytes (CTLs) when pulsed with an antigenic peptide or tumor lysate. In this report, we have used liposome-mediated gene transfer to examine the ability of plasmid DNA encoding the human melanoma-associated antigen gp100 to elicit CD8(+) and CD4(+) T-cell responses. We also compared the efficacy between gp100 gene-modified DCs and naked DNA (pCDNA3/gp100)-based vaccines at inducing anti-tumor immunity. DCs were generated from murine bone marrow and transfected in vitro with plasmid DNA containing the gp100 gene. These gp100-modified DCs (DC/gps) were used to stimulate syngeneic naive spleen T cells in vitro or to immunize mice in vivo. Antigen-specific, MHC-restricted CTLs were generated when DC/gps were used to prime T cells both in vitro and in vivo. Thus, these CTLs were cytolytic for gp100-transfected syngeneic (H-2(b)) tumor MCA106 (MCA/gp) and vaccinia-pMel17/gp100-infected syngeneic B16 and MCA106, but not parental tumor MCA106 and B16, or gp100-transfected allogeneic tumor P815 (H-2(d)). Immunization with DC/gp protected mice from subsequent challenge with MCA/gp but not parental MCA106. Antibody-mediated T-cell subset depletion experiments demonstrate that induction of CTLs in vivo is dependent on both CD4(+) and CD8(+) T cells. Furthermore, DC/gp immunization elicits an antigen-specific CD4(+) T-cell response, suggesting that DC/gps present MHC class II epitopes to CD4(+) T cells. In addition, our data show that gene-modified, DC-based vaccines are more effective than the naked DNA-based vaccines at eliciting anti-tumor immunity in both prophylactic and therapeutic models. These results suggest that the use of DCs transfected with plasmid DNA containing a gene for TAA may be superior to peptide-pulsed DCs and naked DNA-based vaccines for immunotherapy and could provide an alternative strategy for tumor vaccine design.
Copyright 1999 Wiley-Liss, Inc.
Similar articles
-
Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity.Cell Immunol. 1998 May 25;186(1):63-74. doi: 10.1006/cimm.1998.1298. Cell Immunol. 1998. PMID: 9637766
-
Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.J Mol Med (Berl). 2003 Sep;81(9):585-96. doi: 10.1007/s00109-003-0472-5. Epub 2003 Aug 21. J Mol Med (Berl). 2003. PMID: 12937899
-
Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens.J Immunol. 1999 Jul 15;163(2):699-707. J Immunol. 1999. PMID: 10395660
-
Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice.J Surg Oncol. 1998 Jun;68(2):79-91. doi: 10.1002/(sici)1096-9098(199806)68:2<79::aid-jso3>3.0.co;2-h. J Surg Oncol. 1998. PMID: 9624036 Review.
-
Dendritic cell gene therapy.Surg Oncol Clin N Am. 2002 Jul;11(3):645-60. doi: 10.1016/s1055-3207(02)00027-3. Surg Oncol Clin N Am. 2002. PMID: 12487060 Review.
Cited by
-
Gene delivery efficiency in bone marrow-derived dendritic cells: comparison of four methods and optimization for lentivirus transduction.Mol Biotechnol. 2009 Nov;43(3):250-6. doi: 10.1007/s12033-009-9197-1. Epub 2009 Jul 14. Mol Biotechnol. 2009. PMID: 19598009
-
An Endogenous Retrovirus Vaccine Encoding an Envelope with a Mutated Immunosuppressive Domain in Combination with Anti-PD1 Treatment Eradicates Established Tumours in Mice.Viruses. 2023 Apr 6;15(4):926. doi: 10.3390/v15040926. Viruses. 2023. PMID: 37112906 Free PMC article.
-
Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.Cancer Immunol Immunother. 2009 Oct;58(10):1669-77. doi: 10.1007/s00262-009-0678-7. Epub 2009 Feb 19. Cancer Immunol Immunother. 2009. PMID: 19225777 Free PMC article.
-
DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.Cancer Immunol Immunother. 2007 Jan;56(1):1-12. doi: 10.1007/s00262-006-0170-6. Epub 2006 May 5. Cancer Immunol Immunother. 2007. PMID: 16676183 Free PMC article.
-
Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.Mol Biotechnol. 2007 Jun;36(2):131-41. doi: 10.1007/s12033-007-0020-6. Mol Biotechnol. 2007. PMID: 17914192 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials